ClinicalTrials.gg
CompletedNCT06225440IMPRESSUpdated May 13, 2024

Impact of Levagen+® Palmitoylethanolamide (PEA) in a Cross-Over Trial Examining Stress and Cognition in University Students

An interventional study of Levagen+® Palmitoylethanolamide (PEA) and Placebo in Wellness, Psychological and Well-Being, Psychological, sponsored by University of Westminster. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-13.

Sponsored by University of Westminster · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Sep 2022, registered Jan 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 105 studies in Psychological Well-Being with a site in United Kingdom — 34 open to participants now, 39 under way, none of them phase 3. Psychological Well-Being · United Kingdom.

Enrollment
44th of 78
64 · median 82
Started
2022
with 9 others
No phase
75 of 105
22 open now
Registered
67th of 105
by date

Among the 105 studies in Psychological Well-Being with a site in United Kingdom, this one is the 44th largest by enrollment of the 78 interventional ones that give a count, is one of 10 that started in 2022, is one of 75 with no phase, and was the 67th registered.

Psychological Well-Being

2,208 studies on the registry are indexed under Psychological Well-Being; 730 are open to participants now.

Browse Psychological Well-Being studies →

Open to participants now

34 of the 105 studies in Psychological Well-Being with a site in United Kingdom are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 403 Psychological Well-Being studies recruiting now, 223 (55%) set no upper age limit and 155 (38%) stop at 75 or younger; 121 take children under 18; 206 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 105 studies in Psychological Well-Being with a site in United Kingdom, or all of them as a file.
02

Study summary

The goal of this randomised cross-over trial is to learn about the effects of Levagen+® Palmitoylethanolamide (PEA) supplementation on cognition, wellness and well-being in young and healthy university students.

The main question it aims to answer is:

  • Does the PEA supplementation affect parameters of stress, mood, cognition and well-being in university students?

Participants will complete 2 baseline on-site visits during which they will be assigned to Levagen+® Palmitoylethanolamide (PEA) treatment or placebo arm each time and:

  • complete anthropometric measurements, questionnaires and surveys,
  • undergo blood and saliva sampling
  • complete a cognitive assessment (CANTAB)
  • a randomly chosen cohort will also measure heart rate variability (HRV) over 3 days.

Researchers will compare the PEA treatment group to the placebo to see if there is a significant difference.

Read the detailed description

The study will investigate the effect of Levagen+® Palmitoylethanolamide (PEA) supplementation on parameters of stress, well-being and cognition at defined time points. Assessments will be made using a combination of a range of stress measures, which will include physiological and psychometric parameters.

Physiological measures will include assessments of known biomarkers of the principal stress-sensitive physiological systems, the hypothalamic-pituitary-adrenal axis, and the autonomic nervous system, while psychometric measures will include established instruments to assess general health, somatic stress symptoms, academic stress, response to stress, cognition, and mood.

03

Conditions studied

  • Wellness, Psychological
  • Well-Being, Psychological

Keywords

  • nutraceutical
  • palmitoylethanolamide
  • PEA
  • cognition
  • stress
  • inflammation
  • wellness
  • well-being
  • BDNF
  • supplement
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males \& Females
  • 18 to 40 years of age
  • Fully enrolled full-time university students from London

Exclusion criteria

Exclusion Criteria:

  • Consumption of >14 servings of alcohol/week
  • Any learning disability (e.g. dysphasia)
  • Any neurobiological disorders (e.g. autism)
  • Smokers Any allergies/health issues related to items being ingested
  • Any serious illnesses or those on chronic medication
  • Any pregnant or lactating women
  • Any woman who is trying to conceive
  • Any chronic gastrointestinal disorders
  • Any chronic menstrual disorders (e.g. PCOS)
  • Any subjects who have undergone menopause or undergoing the perimenopause transition
  • Any eating disorders
  • Any depression/mental disorders
  • Any obese sedentary (not physically active) individual, according to values
  • Any abnormal blood pressure levels
  • Shift work
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Active comparator
    Levagen+® Palmitoylethanolamide (PEA)

    Levagen+® Palmitoylethanolamide (PEA) - 700mg/day, containing not less than 600 mg PEA.

    Dietary Supplement: Levagen+® Palmitoylethanolamide (PEA)

  • Placebo comparator
    Placebo

    Placebo - Microcrystalline Cellulose

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementLevagen+® Palmitoylethanolamide (PEA)

    Drug page: PalmidrolStudies of PalmidrolPalmidrol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants were instructed to swallow 2 opaque capsules (Levagen+® - 90% of PEA) with water daily at the same time of the day for 6 weeks.

  • Dietary supplementPlacebo

    Participants were instructed to swallow 2 opaque capsules (Microcrystalline Cellulose) with water daily at the same time of the day for 6 weeks.

06

What researchers measure

Primary outcomes

  1. To assess the influence of PEA supplementation on the perceived difficulties of test execution.

    Motor Screening Task (MOT) was used as a screening tool to indicate difficulties in test execution as part of the Core Cognition battery - CANTAB by Cambridge Cognition.

    Time frame: The parameters were measured during the baseline visit (day 1) and during the endpoint visit (day 42) of the 6-week supplementation period.

  2. To assess the influence of PEA supplementation on the reaction and movement speed and attention.

    Reaction Time (RTI) was used to measure reaction and movement speed and attention as part of the Core Cognition battery - CANTAB by Cambridge Cognition.

    Time frame: The parameters were measured during the baseline visit (day 1) and during the endpoint visit (day 42) of the 6-week supplementation period.

  3. To assess the influence of PEA supplementation on visual and episodic memory and visuospatial associative learning.

    Paired Associated Learning (PAL) was used to measure visual and episodic memory and visuospatial associative learning as part of the Core Cognition battery - CANTAB by Cambridge Cognition.

    Time frame: The parameters were measured during the baseline visit (day 1) and during the endpoint visit (day 42) of the 6-week supplementation period.

  4. To assess the influence of PEA supplementation on short-term and spatial working memory and problem solving.

    Spatial Working Memory (SWM) was used to measure short-term and spatial working memory and problem solving as part of the Core Cognition battery - CANTAB by Cambridge Cognition.

    Time frame: The parameters were measured during the baseline visit (day 1) and during the endpoint visit (day 42) of the 6-week supplementation period.

  5. To assess the influence of PEA supplementation on visual processing, recognition, and sustained attention.

    Rapid Visual Information Processing (RVP) was used to assess visual processing, recognition, and sustained attention as part of the Core Cognition battery - CANTAB by Cambridge Cognition.

    Time frame: The parameters were measured during the baseline visit (day 1) and during the endpoint visit (day 42) of the 6-week supplementation period.

  6. To assess the influence of PEA supplementation on Serum Brain-derived neurotrophic factor (BDNF) levels.

    Serum BDNF levels were measured.

    Time frame: The parameters were measured at the baseline visit (day 1) and at the endpoint visit (day 42) of the 6-week supplementation period.

Secondary outcomes

  1. To assess the influence of PEA supplementation on HRV in female population.

    HRV was measured for 3 full days.

    Time frame: The parameters were measured for 3 continuous days following the baseline visit (day 1, day 2 and day 3) and for 3 continuous days following the endpoint visit (day 42, day 43 and day 44) of the study period.

  2. To study the influence of PEA supplementation on the degree of perceived stress in females.

    The Perceived Stress Scale (PSS) a 10-item questionnaire was used to measure the degree to which situations in the participant's life were appraised as stressful. The questions investigate how often certain feelings and thoughts were experienced on a five-point scale from 'never' to 'very often' (never =0, almost never = 1, sometimes = 2, fairly often = 3 and very often = 4) during the 3-day observation periods. To calculate a total PSS score, responses to the four positively stated items (items 4, 5, 7 and 8) first need to be reversed (i.e. 0 =\> 4; 1 =\> 3; 2 =\> 2; 3 =\> 1; 4 =\> 0). The PSS score were then obtained by summing across all items. Higher scores indicate higher levels of perceived stress.

    Time frame: The parameters were measured for 3 continuous days following the baseline visit (day 1, day 2 and day 3) and for 3 continuous days following the endpoint visit (day 42, day 43 and day 44) of the study period.

  3. To study the influence of PEA supplementation on perceived emotions in females.

    The Positive and Negative Affect Schedule (PANAS) was used to assess feelings of both positive and negative emotions experienced simultaneously.

    Time frame: The parameters were measured for 3 continuous days following the baseline visit (day 1, day 2 and day 3) and for 3 continuous days following the endpoint visit (day 42, day 43 and day 44) of the study period.

  4. To study the influence of PEA supplementation on well-being in females.

    Student Well-being Process Questionnaire (WPQ) a 44-item questionnaire was used to examine predictors of positive well-being, adverse mental health, and cognitive function. The responses to questions 1 - 42 were assessed on a 10-point scale and or questions 43 and 44 on a 4-point scale. Where with outcomes related to positive well-being high scores = more positive; with outcomes related to adverse mental health high scores = more negative and with outcomes related to cognitive function high scores = more cognitive problems. Positive well-being was predicted by high positive personality, high social support and low stressor and low negative coping scores. Negative outcomes were predicted by high stressor, coping and conscientiousness scores, and low positive personality and low social support scores. Cognitive problems were predicted by high stressor and negative coping scores and low positive personality scores.

    Time frame: The parameters were measured for 3 continuous days following the baseline visit (day 1, day 2 and day 3) and for 3 continuous days following the endpoint visit (day 42, day 43 and day 44) of the study period.

  5. To assess the influence of PEA supplementation on parameters of inflammation.

    Interferon-gamma (pg/mL), Interleukin-1 beta (pg/mL), Interleukin 6 (pg/mL), Interleukin 10 (pg/mL), Tumour necrosis factor alpha (pg/mL) levels were measured.

    Time frame: The parameters were measured at the baseline visit (day 1) and at the endpoint visit (day 42) of the 6-week supplementation period.

  6. To assess the influence of PEA supplementation on Salivary Cortisol

    Salivary Cortisol levels were measured during morning, afternoon and evening for 3 days following each baseline and endpoint visit at home.

    Time frame: The parameters were measured in morning and afternoon samples collected over 3 continuous days following the baseline visit (day 1, day 2 and day 3) and 3 continuous days following the endpoint visit (day 42, day 43 and day 44) of the study period.

07

Study locations

1 site
  • University of Westminster
    London, W1W 6UW, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Dec 2023, 15 months.

Of 1,274 non-industry interventional studies with no phase under Psychological Well-Being, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 34. This study's 15 months is below that.

Counting every sponsor, half of 1,317 studies reached it within 16 months; a quarter within 7 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2024
First posted
Jan 26, 2024
StartActual
Sep 1, 2022
Primary completionActual
Dec 31, 2023
CompletionActual
Jan 31, 2024
Last update
May 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06225440
Lead sponsor
University of Westminster
Collaborators
Gencor Pacific Group
Responsible party
Mohammed Gulrez Zariwala (Professor in Translational Physiology, University of Westminster) — Principal investigator
First posted
Jan 26, 2024
Start date
Sep 1, 2022
Primary completion
Dec 31, 2023
Completion
Jan 31, 2024
Last update
May 13, 2024

Study contacts

Mohammed Gulrez Zariwala, PhD
principal investigator · University of Westminster
Sanjoy Deb, PhD
principal investigator · Anglia Ruskin University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palmidrol

Start the discussion